Weijie Liao

Weijie Liao

Auto-generated profile, based on publicly available information

Weijie Liao

Department of Hematology and Oncology, International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2022 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
WLWeijie Liao
Weijie Liao
NXNaihan Xu
Naihan Xu
HZHaowei Zhang
Haowei Zhang
WLWeifang Liao
Weifang Liao
YWYanzhi Wang
Yanzhi Wang
YZYaou Zhang
Yaou Zhang
Background: Persistent hyperglycemia decreases the sensitivity of insulin‐sensitive organs to insulin, owing to which cells fail to take up and utilize glucose, which exacerbates the progression of type 2 diabetes mellitus (T2DM). lncRNAs' abnormal expression is reported to be associated with the progression of diabetes and plays a significant role in glucose metabolism. Herein, we study the detailed mechanism underlying the functions of lncRNA EPB41L4A‐AS1in T2DM.Methods: Data from GEO datasets were used to analyze the expression of EPB41L4A‐AS1 between insulin resistance or type 2 diabetes patients and the healthy people. Gene expression was evaluated by qRT‐PCR and western blotting. Glucose uptake was measured by Glucose Uptake Fluorometric Assay Kit. Glucose tolerance of mice was detected by Intraperitoneal glucose tolerance tests. Cell viability was assessed by CCK‐8 assay. The interaction between EPB41L4A‐AS1 and GCN5 was explored by RNA immunoprecipitation, RNA pull‐down and RNA‐FISH combined immunofluorescence. Oxygen consumption rate was tested by Seahorse XF Mito Stress Test.Results: EPB41L4A‐AS1 was abnormally increased in the liver of patients with T2DM and upregulated in the muscle cells of patients with insulin resistance and in T2DM cell models. The upregulation was associated with increased TP53 expression and reduced glucose uptake. Mechanistically, through interaction with GCN5, EPB41L4A‐AS1 regulated histone H3K27 crotonylation in the GLUT4 promoter region and nonhistone PGC1β acetylation, which inhibited GLUT4 transcription and suppressed glucose uptake by muscle cells. In contrast, EPB41L4A‐AS1 binding to GCN5 enhanced H3K27 and H3K14 acetylation in the TXNIP promoter region, which activated transcription by promoting the recruitment of the transcriptional activator MLXIP. This enhanced GLUT4/2 endocytosis and further suppressed glucose uptake.Conclusion: Our study first showed that the EPB41L4A‐AS1/GCN5 complex repressed glucose uptake via targeting GLUT4/2 and TXNIP by regulating histone and nonhistone acetylation or crotonylation. Since a weaker glucose uptake ability is one of the major clinical features of T2DM, the inhibition of EPB41L4A‐AS1 expression seems to be a potentially effective strategy for drug development in T2DM treatment.

11 November 2020 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
YYYIBIN YANG
YIBIN YANG
YZYuan Zhang
Yuan Zhang
LMLihong Miao
Lihong Miao
WLWeijie Liao
Weijie Liao
WLWeifang Liao
Weifang Liao
PPP1R14B-AS1 is an antisense long non-coding RNA with unknown functions. Herein, gene differential analyses were performed using the data of patients with liver cancer and lung adenocarcinoma (LUAD) from The Cancer Genome Atlas database. PPP1R14B-AS1 was found to be upregulated and also overexpressed in 10 other types of cancers. In addition, PPP1R14B-AS1 overexpression was associated with poor overall prognosis in eight cancers. Furthermore, PPPAR14B-AS1 upregulation was positively associated with worsening development of liver and LUAD cancers and related to poor disease-free survival. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses suggested that PPP1R14B-AS1 strongly participated in regulating cell aerobic respiration processes, such as mitochondrial electron respiration chain and NADH dehydrogenation processes. Cell cytoplasmic and nuclear RNA purification assessment results revealed that PPP1R14B-AS existed in the cell nucleus and cytoplasm. The knockdown of PPP1R14B-AS1 in HepG2 and A549 cells using PPP1R14B-AS1-specific siRNAs decreased mitochondrial respiration as demonstrated by the reduction in basal respiration and ATP production. Moreover, PPP1R14B-AS1 downregulation did not obviously affect cell glycolysis ability. Finally, PPP1R14B-AS1 inhibition inhibited HepG2 and A549 cell migration and proliferation. In summary, our study found for the first time that PPP1R14B-AS1 could be a potential biomarker for cancer diagnosis and that PPP1R14B-AS1 inhibition could be a potentially effective therapy.

14 February 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ZHZhang Haowei
Zhang Haowei
XLXiaolin Li
Xiaolin Li
WLWeijie Liao
Weijie Liao
XQXuan Qin
Xuan Qin
YJYapei Jiang
Yapei Jiang
Naihan XuNaihan Xu
Naihan Xu
The mitochondria-localized deubiquitinase USP30 regulates mitophagy and mitochondrial homeostasis, playing a significant role in the progression of neurodegenerative diseases. However, its role in cancer remains poorly understood. Through metabolism-related gene set enrichment analysis, we identified USP30 as a key modulator of glucose metabolism in cancer cells. Utilizing quantitative proteomic and ubiquitinomic approaches coupled with co-immunoprecipitation assays, we elucidated that USP30 regulates glycolysis by interacting with hexokinase HK1 and HK2, a process dependent on its enzymatic activity. USP30 modulates the ubiquitination profile of HK1 and HK2 by preferentially removing atypical ubiquitin chains, thereby enhancing their stability, mitochondrial localization, VDAC1 binding and hexokinase activity. Lysine 144 emerges as a critical regulatory site for USP30-mediated deubiquitination of HK2. Mutation of K144 enhances HK2 stability, increases its mitochondrial localization and binding to VDAC1, and significantly augments hexokinase activity. Furthermore, the HK2 K144 mutation markedly enhances tumor cell glycolysis, fostering increased proliferation and migration both in vitro and in vivo. These findings underscore USP30 as a novel regulator of glycolysis in cancer cells via modulation of HK2 ubiquitination dynamics, suggesting its potential as a therapeutic target in cancer metabolism.

18 May 2026 in Cell Death & Disease
Verified
Journal Article
Open access
ZHZhang Haowei
Zhang Haowei
XLXiaolin Li
Xiaolin Li
WLWeijie Liao
Weijie Liao
XQXuan Qin
Xuan Qin
YJYapei Jiang
Yapei Jiang
Naihan XuNaihan Xu
Naihan Xu

Verified
Journal Article
Open access
PDF file
WLWeijie Liao
Weijie Liao
Naihan XuNaihan Xu
Naihan Xu
Ubiquitin-specific protease 30 (USP30) is a mitochondrial outer membrane-associated deubiquitinase best known for antagonizing PTEN-induced kinase 1 (PINK1)/Parkin-dependent ubiquitination and suppressing mitophagy. This established role has linked USP30 to mitochondrial quality control and neurodegenerative diseases. However, emerging studies in cancer have expanded the biological scope of USP30, revealing functions that cannot be explained by mitophagy regulation alone. USP30 regulates diverse cancer-associated substrates through deubiquitination, thereby affecting protein abundance, subcellular localization, protein interactions, and downstream transcriptional programs. These substrate-dependent effects influence mitochondrial dynamics, lipid synthesis, glucose and amino acid metabolism, redox homeostasis, apoptosis, ferroptosis, epithelial–mesenchymal transition, cancer stemness, T-cell exhaustion, and therapy resistance. Although most studies indicate tumor-promoting roles of USP30 in hepatocellular carcinoma, breast cancer, colorectal cancer, oral squamous cell carcinoma, ovarian cancer, bladder cancer, prostate cancer, and leukemia models, context-dependent tumor-restraining activities have also been reported. In this Review, we examine cancer-associated functions of USP30 that extend beyond its established role in PINK1/Parkin-dependent mitophagy, discuss the spatial and substrate-dependent mechanisms underlying these activities, and highlight opportunities and challenges for therapeutic targeting.